#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating women with sexual dysfunction or low libido need current evidence on cannabis’s potential effects to provide informed counseling, as patients increasingly self-treat with cannabis products. Understanding the emerging research on cannabinoids and sexual function allows providers to discuss both potential benefits and risks, including drug interactions and psychoactive effects that may impact treatment decisions. As cannabis legalization expands access, clinicians should develop competency in discussing sexual health outcomes with patients who use or are considering cannabis.
Recent evidence suggests cannabis use may be associated with improvements in sexual function and intimacy among women, a finding that expands the clinical understanding of cannabinoids beyond pain and nausea management. The research indicates potential mechanisms through which cannabis compounds may enhance arousal, orgasm, and overall sexual satisfaction, though most studies remain preliminary and often rely on self-reported outcomes without rigorous control groups. Clinicians should recognize that some patients may report improved sexual health as a cannabis use benefit, which could influence treatment preferences and adherence discussions, particularly for women experiencing sexual dysfunction related to anxiety or reduced libido. However, the evidence base remains limited compared to established indications, and confounding variables such as reduced anxiety or improved relationship dynamics are difficult to isolate from direct pharmacological effects. Clinicians counseling women about cannabis should acknowledge potential sexual health benefits as one possible outcome while emphasizing the need for larger, well-controlled trials before making this an indication for recommendation. When patients raise sexual function as a motivation for cannabis use or inquiry, clinicians can incorporate this as part of a holistic assessment while noting that evidence-based treatments for sexual dysfunction remain the first-line approach.
“The evidence we’re seeing on cannabinoids and sexual function in women is compelling enough that I now routinely ask about cannabis use during sexual health assessments, the same way I ask about other medications or supplements, because patients deserve an informed conversation about what might actually help them rather than defaulting to pharmaceuticals that often come with their own sexual side effects.”
🏥 While emerging observational data suggest potential benefits of cannabis on sexual function in some women, healthcare providers should approach these findings with appropriate caution given significant methodological limitations in current research, including small sample sizes, self-selection bias, and difficulty controlling for confounding variables such as relationship quality, stress reduction, or placebo effects. The endocannabinoid system’s role in sexual response is plausible but incompletely understood, and individual responses to cannabis vary considerably based on dose, cannabinoid profile, frequency of use, and underlying health conditions. Importantly, cannabis use carries its own risks including potential impacts on fertility, pregnancy outcomes, and cognitive function that must be weighed against any perceived sexual benefits. When patients inquire about cannabis for sexual health concerns, clinicians can acknowledge the preliminary interest in this area while emphasizing that robust clinical trials are lacking and recommending evidence-based first-line approaches to sexual dysfunction such as addressing relationship factors,
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: